Effect of pan-retinal laser photocoagulation on plasma VEGF, endothelin-1 and nitric oxide in PDR

International Journal of Ophthalmology

Volumn 3, Issue 1, 2010, Pages 19-22

  Mohamed, Tarek Ahmed ^a   Mohamed, Sahar El Deek ^a  

^a ASSIUT UNIVERSITY   (Egypt)

Author keywords

Diabetic retinopathy; Endothelin 1; Microangiopathy; Nitric oxide; Panretinal photocoagulation; Vascular endothelial growth factor

Indexed keywords

EID: 84895188775     PISSN: 22223959     EISSN: 22274898     Source Type: Journal    
DOI: 10.3980/j.issn.2222-3959.2010.01.05     Document Type: Article

References (27)

1. Sulochana KN, Ramakrishnan S, Rajesh M, Coral K, Badrinath SS. Diabetic retinopathy: molecular mechanisms, present regime of treatment and future prospectives. Curr Sci. 2001;80(2):133-142.
2. Klein R, Klein BE, Moss SE, Davis MD, DeMets DL. The Wisconsin epidemiologic study of diabetic retinopathy. III. Prevalence and risk of diabetic retinopathy when age at diagnosis is 30 or more years. Arch Ophthalmol. 1984;102(4)527-532. [PubMed]
3. Caine GJ, Blann AD, Stonelake PS, Ryan P, Lip GY. Plasma angiopoietin-1, angiopoietin-2 and Tie-2 in breast and prostate cancer: a comparison with VEGF and Flt-1. Eur J Clin Invest. 2003;33(10):883-890. [PubMed]
4. Aeillo LP, Avery RL, Arigg PG, Keyt BA, Jampel HD, Shah ST, Pasguale LR, Thieme H, Iwamoto MA, Park SE. Vascular endothelial growth factor in ocular fluids of patients with diabetic retinopathy and other retinal disorders. N Engl J Med. 1994;331(22):1480-1487. [PubMed]
5. Marsden PA, Heng HH, Scherer SW, Stewart RJ, Hall AV, Shi XM, Tsui LC, Schappert KT. Structure and chromosomal localization of the human constitutive endothelial nitric oxide synthase gene. J Biol Chem. 1993;268(23):17478-17488. [PubMed]
6. Li H, Forstermann U. Nitric oxide in the pathogenesis of vascular disease. J Pathol. 2000;190(3):244-254. [PubMed]
7. Mangiafico RA, Malatino LS, Santonocito M, Spada RS. (Plasma endothelin-1 concentrations in non-insulin-dependent diabetes mellitus and nondiabetic patients with chronic arterial obstructive disease of the lower limbs. Int Angiol. 1998;17(2):97-102. [PubMed]
8. Chaturvedi N, Sjolie AK, Stephenson JM, Abrahamian H, Keipes M, Castellarin A, Rogulja-Pepeonik Z, Fuller JH. Effect of lisinopril on progression of retinopathy in normotensive people with type 1 diabetes. The EUCLID Study Group. EURODIAB Controlled Trial of Lisinopril in Insulin-Dependent Diabetes Mellitus. Lancet. 1998;351(9095):28-31. [PubMed]
9. Pe'er J, Folberg R, Itin A, Gnessin H, Hemo I, Keshet E. Upregulated expression of vascular endothelial growth factor in proliferative diabetic retinopathy. Br J Ophthalmol. 1996;80(3):241-245. [PMC free article] [PubMed]
10. Kondo S, Asano M, Matsuo K, Ohmori I, Suzuki H. Vascular endothelial growth factor/vascular permeability factor is detectable in the sera of tumour-bearing mice and cancer patients. Biochim Biophys Acta. 1994;1221(2):211-214. [PubMed]
11. Takakuwa T, Endo S, Nakae H, Kikichi M, Suzuki T, Inada K, Yoshida M. Plasma levels of TNF-alpha, endothelin-1and thrombomodulin in patients with sepsis. Res Commun Chem Pathol Pharmacol. 1994;84(3):261-269. [PubMed]
12. van Bezooijen RL, Que I, Ederveen AG, Kloosterboer HJ, Papapoulos SE, Lowik CW. Plasma nitrate+nitrite levels are regulated by ovarian steroids but do not correlate with trabecular bone mineral density in rats. J Endocrinol. 1998;159(1):27-34. [PubMed]
13. Caldwell RB, Bartoli M, Behzadian MA, El-Remessy AE, Al-Shabrawey M, Platt DH, Caldwell RW. Vascular endothelial growth factor and diabetic retinopathy: pathophysiological mechanisms and treatment perspectives. Diabetes Metab Res Rev. 2003;19(6):442-455. [PubMed]
14. Lip PL, Belgore F, Blann AD, Hope-Ross MW, Gibson JM, Lip GY H. Plasma VEGF and soluble VEGF receptor Flt-1 in proliferative retinopathy: relationship to endothelial dysfunction and laser treatment. Invest Ophthalmol Vis Sci. 2000;41(18):2115-2119. [PubMed]
15. Lip PL, Chatterjee S, Cain GJ, Hope-Ross M, Gibson JM, Blann AD, Lip GY H. Plasma vascular endothelial growth factor, angiopoietin-2, and soluble angiopoietin receptor tie-2 in diabetic retinopathy: effects of laser photocoagulation and angiotensin receptor blockade. Br J Ophthalmol. 2004;88(12):1543-1546. [PMC free article] [PubMed]
16. Shinoda K, Ishida S, Kawashima S, Wakabayashi T, Matsuzaki T, Takayama M, Shinmura K, Yamada M. Comparison of the levels of hepatocyte growth factor in aqueous fluid and serum with grades of retinopathy in patients with diabetes mellitus. Br J Ophthalmol. 1999;83(7):834-837. [PMC free article] [PubMed]
17. Kozawa T, Sone H, Okuda Y, Kawakami Y, Sekine Y, Imai M, Hommura S, Inatomi M, Yaguchi S, Matsuo K, Segawa T, Suzuki H, Yamashita K. Vascular endothelial growth factor levels in the aqueous and serum in diabetic retinopathy with or without neovascular glaucoma. Nippon. Ganka Gakkai Zasshi. 1998;102(11):73l-738. [PubMed]
18. Webb NJ, Bottomley MJ, Watson CJ, Brenchley PEC. Vascular endothelial growth factor (VEGF) is released from platelets during blood clotting: implications for measurement of circulating VEGF levels in clinical disease. Clin Sci. 1998;94(4):395-404. [PubMed]
19. Bursell SE, Clermont AC, Oren B, King GL. The in vivo effect of endothelins on retinal circulation in nondiabetic and diabetic rats. Invest Ophthalmol Vis Sci. 1995;36(3):596-607. [PubMed]
20. Zhu H, Shi CH. Analysis of the diagnostic value of plasma endothelin for diabetic retinopathy using the receiver operating characteristic curve. Ophthalmic Res. 2007;39(5)289-293. [PubMed]
21. Kawamura M, Ohgawara H, Naruse M, Suzuki N, Iwasaki N, Naruse K, Hori S, Demura H, Omori Y. Increased plasma endothelin in NIDDM patients with retinopathy. Diabetes Care. 1992;15(10):1396-1397. [PubMed]
22. Laurenti O, Vingolo EM, Desideri GB, Ferri C, Bellini C, Cassone-Faldetta M, Santucci A, De Mattia G. Increased levels of plasma endothelin-1 in non-insulin dependent diabetic patients with retinopathy but without other diabetes-related organ damage. Exp Clin Endocrinol Diabetes. 1997;l05:40-42. [PubMed]
23. Chakravarthy U, Hayes RG, Stitt AW, Douglas A. Endothelin expression in ocular tissues of diabetic and insulin-treated rats. Invest Ophthalmol Vis Sci. 1997;38(10):2144-2151. [PubMed]
24. Kakizawa H, Itoh M, Itoh Y, Imamura S, Ishiwata Y, Matsumoto T, Yamamoto K, Kato T, Ono Y, Nagata M, Hayakawa N, Suzuki A, Goto Y, Oda N. The relationship between glycemic control and plasma vascular endothelial growth factor and endothelin-1 concentration in diabetic patients. Metabolism. 2004;53(5)550-555. [PubMed]
25. Davies MG, Hagen PO. The vascular endothelium. A new horizon. Ann Surg. 1993;218(5):593-609. [PMC free article] [PubMed]
26. Izumi N, Nagaoka T, Mori F, Sato E, Takahashi A, Yoshida A. Relation between plasma nitric oxide levels and diabetic retinopathy. Jpn J Ophthalmol. 2006;50(5)465-468. [PubMed]
27. Aydn A, Orhan H, Sayal A, Ozata M, Sahin G, Ismier A. Oxidative stress and nitric oxide related parameters in type II diabetes mellitus: effects of glycemic control. Clin Biochem. 2001;34(1):65-70. [PubMed]